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Introduction
Dyslipidemia is a high level of lipids (cholesterol, triglyc-
erides [TGs], or both) carried by lipoproteins in the blood. 
This term includes hyperlipoproteinemia (hyperlipid-
emia), which refers to abnormally high levels of total cho-
lesterol, low density lipoprotein (LDL-C) or TG, as well as 
an abnormally low level of high density lipoprotein (HDL-
C). Hyperlipidemia can have a serious effect on health (1). 
It can significantly increase the risk of developing cardio-
vascular disease, including disease of blood vessels sup-
plying the heart (coronary artery disease), brain (cerebro-
vascular disease), and limbs (peripheral vascular disease) 
(2). Diet, physical activity and drugs are main treatments 
for hyperlipidemia (3). The available drugs have some side 
effects, so recently attention has been turned to the use 
of medicinal plants that have usually less side effects and 
are accepted by people as an alternative therapy since the 
earliest times (4). Traditional herbal medicines are getting 
significant attention in global health debates (5,6). One 
of the herbs is Kelussia odoratissima. This plant is from 
Umbelliferae family and is harvested in April and in a re-
stricted region in west of Iran. Kelussia is a perennial and 
very aromatic. This plant is used to treat some diseases 
such as rheumatologic disease, hypertension, blood lipid 
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Introduction: Hyperlipidemia is associated with increased risk of cardiovascular disease. 
Each type of medication works differently and has different types of side effects. Flavonoids 
are a group of polyphenolic compounds with antioxidant properties that help reducing the 
cardiovascular risk factors. Kelussia odoratissima is a flavonoid containing plant. 
Objectives: The aim of this study was investigating the effect of this herb on lipid and glucose 
profile in hyperlipidemia patients. 
Patients and Methods: This study performed on 61 hyperlipidemia patients. They assigned 
in control and intervention groups. The control group received 40 mg/day of lovastatin 
and intervention group received 40 mg/day of Lovastatin plus 2 g/day powder of Kelussia 
odoratissima. Before, two weeks and 1 month after the beginning of the study, cholesterol, 
triglyceride (TG), low density lipoprotein cholesterol (LDL-C), very low density lipoprotein 
cholesterol (VLDL-C), high density lipoprotein cholesterol (HDL-C), and fasting blood sugar 
(FBS) were measured. Data were analyzed by variance analysis with repeated measures, chi-
square and t tests. 
Results: The reduction rate of cholesterol, TG, VLDL-C and LDL-C was similar in the control 
and intervention groups. The HDL-C rate was higher in intervention group compared to 
control group (P < 0.05). The mean LDL/HDL ratio decreased during the study (P < 0.001); 
however, there was not any significant difference between the two groups (P > 0.05). The mean 
of FBS did not change between and within groups (P > 0.05).
Conclusion: Kelussia odoratissima did not have a desirable effect on serum lipid profile and 
FBS in hyperlipidemic patients that use lovastatin, but is able to increase HDL-C significantly. 
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abnormalities, common cold, and stomachache in local 
area. Studies have shown that it has anti-diabetes, anti-in-
flammation, and anti-allergy effects due to its flavonoids 
(7). Butyl phthalide and ligustilide are the main compo-
nents of Kelussia odoratissima. Phthalides constitutes 70% 
of the plant extract with the effect of prostaglandin F2α 
inhibition, liver disorders therapy and blood viscosity re-
duction and the ligustilide leads to relax vessels of rat (8). 
Also the effectiveness of this plant in treating hyperlipid-
emia is verified in animal studies but no research has been 
done relating to this effect in human. So, the aim of this 
study was evaluating this effect in clinical practice. 
Patients and Methods
This clinical trial study carried out on 61 hyperlipidemic 
patients. The patients had no liver, kidney or infectious 
diseases and referred to the Internal Clinic of Shahrekord 
University of Medical Sciences. Every patient with at least 
one of the following criteria in the serum lipid profile was 
recognized as a hyperlipidemic patient (9). A cholesterol 
level above 240 ml/dl, TG level above 200 ml/dl, HDL-C 
level below 50 ml/dl and LDL-C level above 130 ml/dl.
They assigned into two intervention and control groups 
ordered by their arrival. Among all the patients, 30 were 
placed in the intervention group, and 31 in the control 
group. Patients were asked to avoid making any change in 
their diet during the study and they were asked to inform 
the researchers in case of any change in their diet or their 
medications, to be excluded. Patients of the intervention 
group received lovastatin (40 mg/day) along with pack-
ages including 60 g of Kelussia odoratissima plus a con-
tainer having the capacity of 2 g. The patients of this group 
were asked to take 2 g of the powder in 150 cc low-fat yo-
gurt at the lunch time without making any change in their 
food diet. The control group was asked to have lovastatin 
(40 mg/day) along with 150 cc low-fat yogurt at the lunch 
time. Two weeks and also 1 month after starting the study, 
all the patients underwent biochemical tests including 
cholesterol, TG, LDL-C, HDL-C, VLDL and fasting blood 
sugar (FBS) at the same laboratory (by BT3000 auto-ana-
lyzer) and the results were registered in separate files re-
lated to each patient. The personnel of the laboratory did 
not have any information about the studied groups. 
Ethical issues
1) The research followed the tenets of the Declaration of 
Helsinki; 2) Informed consent was obtained; and 3) the 
proposal of the research was approved in the Ethics Com-
mittee of Shahrekord University of Medical Sciences.
Statistical analysis
After completing the above stages, the obtained data were 
analyzed by variance analysis with repeated measures, chi-
square and t tests. P value with rate of less than 0.05 was 
considered as significant level.
Results
In this study, 30 patients participated as the intervention 
group and 31 as the control group. Chi-square test did not 
show any significant difference between the two groups 
regarding gender, being urban or villager, education level, 
the type of consumed oil in diet, the type of daily activities 
and the drug history (P > 0.05).
The results showed that the reduction rate of cholesterol, 
TG, VLDL-C and LD-CL was similar in the control (lov-
astatin, 40 mg/day) and intervention (lovastatin 40 mg/
day and Kelussia odoratissima powder, 2 g/day) groups. 
The difference HDL-C rate was significant before and af-
ter study in the two groups; this difference increased in 
the intervention group with the average rate of 5.5 units 
and decreased in control group with the average rate of 
2.5 units (P < 0.05).
The mean LDL/HDL ratio decreased during the study 
(P < 0.001); however, there was not any significant differ-
ence between the two groups (P > 0.05). The mean of FBS 
did not change and the two groups had no significant dif-
ference (P > 0.05; Table 1).
Discussion
The results of study showed that cholesterol, LDL-C, 
Table 1. The changes of biochemical factorsa in hyperlipidemic patients after taking Kelussia odoratissima in the patients who take 
lovastatin
Variable
Groups
Control Case
Before intervention 2 weeks later 1 month later Before intervention 2 weeks later 1 month later
Cholesterol 246.67±46.28 176.16±43.61 171.70±33.10 247.10±47.99 177.30±57.02 180.23±45.29
TG 265.29±174.87 177.74±85.08 191.03±85.66 305.36±218.98 235.40±275.52 228.56±206.86
LDL-C 138.86±42.08 89.49±41.75 83.51±35.63 138.28±44.20 74.44±51.53 88.60±40.71
VLDL 58.52±36.60 34.16±13.29 37.90±17.27 62.36±41.68 40.60±26.45 40.66±24.23
HDL/LDL 2.60±0.61 1.70±0.71 1.70±0.79 2.97±1.1 1.74±1.02 1.75±0.90
FBS 116.79±45.62 121.16±50.81 111.93±42.67 116.26±42.17 115.46±53.28 120.96±58.52
Abbreviations: LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; VLDL-C: very low density lipoprotein cholesterol; 
FBS, fasting blood sugar.
P < 0.001 during the study in both groups for all variables except FBS. P > 0.05 between the two groups during the study in all variables, case group 
receiving Lovastatin (40 mg/day) and Kelussia odoratissima Mozaffarian (2 g/day), control group receiving Lovastatin (40 mg/day).
a Due to the existence of difference between the two groups in the rate of HDL before consuming the drug, the difference in the rate of HDL was 
analyzed at the beginning and the end of the study, so that in the case group it has increased 5.5 units and in the control group it has decreased 2.5 
units (P < 0.05).
Journal of Nephropharmacology, Volume 6, Number 1, January 2017http://www.jnephropharmacology.com 11
 Kelussia odoratissima, serum lipid and FBS
VLDL-C and TG had a significant reduction during the 
study. However, this rate of reduction was not statistically 
significant in control and intervention group. The differ-
ence HDL-C rate was significant before and after study 
in the two groups; this difference increased in the inter-
vention group with the average rate of 5.5 units and de-
creased in control group with the average rate of 2.5 units. 
The mean of LDL/HDL ratio decreased during the study. 
However, there was no significant difference between the 
two groups. The mean of FBS had no change during the 
study and both groups were similar in this respect. 
Different studies have shown that Kelussia odoratissima 
have flavonoid combinations (10). The fraction analy-
sis of the total extract of the plant has shown the routine 
existence of 3, 4, 7-trihydroxyflavone, caffeic acid, and 
phthalide. Since mentioned flavonoids are all in form of 
aglycone, they have fast intestinal absorption due to the 
specific structure (7). Therefore, the lipid decrease was ex-
pected after the use of Kelussia odoratissima Mozaffarian. 
Also caffeic acid in this plant has antioxidant properties 
which can decrease harmful lipids through inhibition of 
cholesterol biosynthesis. The cholesterol synthesis regula-
tion is normally done by HMG-CoA. The conversion re-
action of HMG-CoA to mevalonate takes place by the me-
diation of HMG-CoA reductase and NADPH (Nicotine 
amide adenine dinucleotide phosphate) that is the main 
affecting point of statins antihypercholesterolemic agents 
(11). One explanation for our result is taking lovastatin as 
treatment in both intervention and control groups. Since 
researchers could not deprive patients from taking drug 
in the human study due to ethical issues. Taking lovas-
tatin will lead the level of lipid to a normal level. This issue 
causes that the consumption of the plant cannot decrease 
the lipid easily.
Flavonoids increase the level of HDL-C through increas-
ing ApoA-I synthesis; therefore, increasing the level of 
HDL-C is probably due to existence of flavonoid contents 
of Kelussia odoratissima in the intervention group (12). 
The LDL/HDL ratio decreased. This ratio is highly signifi-
cant in predicting the rate of coronary diseases. This rela-
tion can be justified with the roles suggested for LDL-C in 
transferring cholesterol to tissues and the role of HDL-C 
in the reverse transfer of cholesterol (13).
Herbal antioxidants may also have insulin like effect and 
increase the absorption of glucose in peripheral tissues 
(14). Moreover, antioxidants increase the secretion of 
insulin and decrease the amount of glucose in the body 
through affecting beta cells. However, in this study, taking 
Kelussia odoratissima did not make any change in patients’ 
blood glucose in spite of expectations. This issue can be 
probably due to the limitations that exist despite the nec-
essary trainings of patients on controlling their diet and 
activity. This issue needs further research anyway. Kelussia 
odoratissima increased the HDL-C level which is an indi-
cator for increase in serum antioxidant capacity. Oxida-
tive stress has a predominant contribute to cardiovascular 
diseases, especially atherosclerosis as well as most of hard 
curable diseases cancer, diabetes and infections (13). An-
tioxidants have been shown to counteract the toxic effects 
of free radicals preventing a lot of free radicals induced 
diseases. Therefore, increase in antioxidant capacity of the 
body by this plant may promote beneficial effects in these 
complications. There are a lot of medicinal plants which 
have antioxidant activity which may have the same effects 
on these diseases (15). 
Therefore, performing long-term studies on the effect of 
normal antioxidants and especially Kelussia odoratissima 
on lipid and glucose of hyperlipidemic patients seems 
necessary.
Conclusion
In this study adding the Kelussia odoratissima powder 
to the diet of hyperlipidemic patients did not cause any 
considerable difference except increasing HDL-C in com-
parison with patients who took their routine medications. 
Therefore, performing long-term studies on the effect of 
normal antioxidants and especially Kelussia odoratissima 
on lipid and glucose of hyperlipidemic patients seems 
necessary.
Limitations of the study
This study was conducted on a small group of patients. We 
suggest larger studies on this subject.
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